LOVE Stock Overview
Engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Cannara Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.75 |
| 52 Week High | CA$1.04 |
| 52 Week Low | CA$0.52 |
| Beta | 1.13 |
| 11 Month Change | 0% |
| 3 Month Change | 15.38% |
| 1 Year Change | -13.79% |
| 33 Year Change | -46.43% |
| 5 Year Change | -42.31% |
| Change since IPO | -75.41% |
Recent News & Updates
Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share Price
Nov 26
These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Recent updates
Benign Growth For Cannara Biotech Inc. (CVE:LOVE) Underpins Its Share Price
Nov 26These 4 Measures Indicate That Cannara Biotech (CVE:LOVE) Is Using Debt Extensively
Oct 29Cannara Biotech Inc.'s (CVE:LOVE) 33% Price Boost Is Out Of Tune With Earnings
Aug 22Cannara Biotech (CVE:LOVE) Shareholders Will Want The ROCE Trajectory To Continue
Aug 21Does Cannara Biotech (CVE:LOVE) Have A Healthy Balance Sheet?
Jul 14Cannara Biotech Inc.'s (CVE:LOVE) Prospects Need A Boost To Lift Shares
May 09Here's Why We Think Cannara Biotech (CVE:LOVE) Might Deserve Your Attention Today
Feb 28Investor Optimism Abounds Cannara Biotech Inc. (CVE:LOVE) But Growth Is Lacking
Jan 24Cannara Biotech's (CVE:LOVE) Earnings May Just Be The Starting Point
Dec 18Is Cannara Biotech (CVE:LOVE) A Risky Investment?
Jul 29Cannara Biotech Inc.'s (CVE:LOVE) Business Is Yet to Catch Up With Its Share Price
Apr 10Here's Why Cannara Biotech (CVE:LOVE) Has A Meaningful Debt Burden
Jan 26Cannara Biotech's (CVE:LOVE) Earnings Aren't As Good As They Appear
Jan 27Cannara Biotech (CVE:LOVE) Has A Somewhat Strained Balance Sheet
Dec 10Here's Why Cannara Biotech (CSE:LOVE) Can Afford Some Debt
Mar 16Can You Imagine How Cannara Biotech's (CSE:LOVE) Shareholders Feel About The -6.5% Share Price Increase?
Jan 22
Have Insiders Been Buying Cannara Biotech Inc. (CSE:LOVE) Shares?
Dec 18Shareholder Returns
| LOVE | CA Personal Products | CA Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 0.6% |
| 1Y | -13.8% | -0.5% | 23.1% |
Return vs Industry: LOVE underperformed the Canadian Personal Products industry which returned -0.5% over the past year.
Return vs Market: LOVE underperformed the Canadian Market which returned 23.1% over the past year.
Price Volatility
| LOVE volatility | |
|---|---|
| LOVE Average Weekly Movement | 12.8% |
| Personal Products Industry Average Movement | 9.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: LOVE has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: LOVE's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | n/a | Zohar Krivorot | cannara.ca |
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivated products in Canada. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations.
Cannara Biotech Inc. Fundamentals Summary
| LOVE fundamental statistics | |
|---|---|
| Market cap | CA$69.31m |
| Earnings (TTM) | CA$6.44m |
| Revenue (TTM) | CA$81.75m |
10.5x
P/E Ratio0.8x
P/S RatioIs LOVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LOVE income statement (TTM) | |
|---|---|
| Revenue | CA$81.75m |
| Cost of Revenue | CA$51.96m |
| Gross Profit | CA$29.79m |
| Other Expenses | CA$23.35m |
| Earnings | CA$6.44m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.072 |
| Gross Margin | 36.44% |
| Net Profit Margin | 7.88% |
| Debt/Equity Ratio | 54.2% |
How did LOVE perform over the long term?
See historical performance and comparison